FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006638330> ?p ?o ?g. }

• W3006638330 endingPage "194" @default.
• W3006638330 startingPage "182" @default.
• W3006638330 abstract "FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were recently introduced for metastatic pancreatic cancer treatment. However, studies that compared these two regimens and studies in Asian populations are lacking.To compare the treatment outcomes of FOLFIRINOX and Gem + nabPTX regimen for metastatic pancreatic cancer treatment in Korean population.Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX (n = 86) or Gem + nabPTX (n = 81) as the first-line since January 2015 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry. Treatment efficacy, treatment-related adverse events and economic aspects were compared.Patients in the FOLFIRINOX group were significantly younger (54 vs 65 years; P < 0.001) and had better performance statuses at diagnosis. The median overall survival (10.7 vs 12.1 mo; P = 0.157), progression-free survival (8.0 vs 8.4 mo; P = 0.134), and objective response rates (33.7% vs 46.9%; P = 0.067) were not significantly different when compared with Gem + nabPTX group. Grade ≥ 3 neutropenia and gastrointestinal adverse events were more common in the FOLFIRINOX group. The drug costs of both regimens were similar.Treatment efficacy and economic burdens were comparable between the two regimens. But, the details of adverse event were different. Gem + nabPTX regimen might be considered preferentially in certain conditions." @default.
• W3006638330 created "2020-02-24" @default.
• W3006638330 creator A5003581837 @default.
• W3006638330 creator A5020189698 @default.
• W3006638330 creator A5035695627 @default.
• W3006638330 creator A5046089418 @default.
• W3006638330 creator A5050431257 @default.
• W3006638330 creator A5052238082 @default.
• W3006638330 creator A5052632851 @default.
• W3006638330 creator A5070000246 @default.
• W3006638330 creator A5084067051 @default.
• W3006638330 creator A5087762681 @default.
• W3006638330 creator A5089138431 @default.
• W3006638330 date "2020-02-15" @default.
• W3006638330 modified "2023-10-11" @default.
• W3006638330 title "FOLFIRINOX <i>vs</i> gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study" @default.
• W3006638330 cites W1931508686 @default.
• W3006638330 cites W1992918749 @default.
• W3006638330 cites W2019607817 @default.
• W3006638330 cites W2023335214 @default.
• W3006638330 cites W2052416547 @default.
• W3006638330 cites W2061132293 @default.
• W3006638330 cites W2077299691 @default.
• W3006638330 cites W2090763515 @default.
• W3006638330 cites W2097117460 @default.
• W3006638330 cites W2104631255 @default.
• W3006638330 cites W2106737419 @default.
• W3006638330 cites W2117105709 @default.
• W3006638330 cites W2136866696 @default.
• W3006638330 cites W2151253787 @default.
• W3006638330 cites W2156791166 @default.
• W3006638330 cites W2158134441 @default.
• W3006638330 cites W2158798157 @default.
• W3006638330 cites W2161869158 @default.
• W3006638330 cites W2165480504 @default.
• W3006638330 cites W2166615754 @default.
• W3006638330 cites W2170566133 @default.
• W3006638330 cites W2187917981 @default.
• W3006638330 cites W2235523093 @default.
• W3006638330 cites W2317504614 @default.
• W3006638330 cites W2323248054 @default.
• W3006638330 cites W2345269414 @default.
• W3006638330 cites W2415398754 @default.
• W3006638330 cites W2548931019 @default.
• W3006638330 cites W2608473363 @default.
• W3006638330 cites W2735949777 @default.
• W3006638330 cites W2782775232 @default.
• W3006638330 cites W2915177178 @default.
• W3006638330 cites W4210976084 @default.
• W3006638330 doi "https://doi.org/10.4251/wjgo.v12.i2.182" @default.
• W3006638330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7031147" @default.
• W3006638330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32104549" @default.
• W3006638330 hasPublicationYear "2020" @default.
• W3006638330 type Work @default.
• W3006638330 sameAs 3006638330 @default.
• W3006638330 citedByCount "35" @default.
• W3006638330 countsByYear W30066383302020 @default.
• W3006638330 countsByYear W30066383302021 @default.
• W3006638330 countsByYear W30066383302022 @default.
• W3006638330 countsByYear W30066383302023 @default.
• W3006638330 crossrefType "journal-article" @default.
• W3006638330 hasAuthorship W3006638330A5003581837 @default.
• W3006638330 hasAuthorship W3006638330A5020189698 @default.
• W3006638330 hasAuthorship W3006638330A5035695627 @default.
• W3006638330 hasAuthorship W3006638330A5046089418 @default.
• W3006638330 hasAuthorship W3006638330A5050431257 @default.
• W3006638330 hasAuthorship W3006638330A5052238082 @default.
• W3006638330 hasAuthorship W3006638330A5052632851 @default.
• W3006638330 hasAuthorship W3006638330A5070000246 @default.
• W3006638330 hasAuthorship W3006638330A5084067051 @default.
• W3006638330 hasAuthorship W3006638330A5087762681 @default.
• W3006638330 hasAuthorship W3006638330A5089138431 @default.
• W3006638330 hasBestOaLocation W30066383301 @default.
• W3006638330 hasConcept C121608353 @default.
• W3006638330 hasConcept C126322002 @default.
• W3006638330 hasConcept C143998085 @default.
• W3006638330 hasConcept C197934379 @default.
• W3006638330 hasConcept C2776694085 @default.
• W3006638330 hasConcept C2777063308 @default.
• W3006638330 hasConcept C2777148230 @default.
• W3006638330 hasConcept C2780210213 @default.
• W3006638330 hasConcept C2780258809 @default.
• W3006638330 hasConcept C2780259306 @default.
• W3006638330 hasConcept C2781413609 @default.
• W3006638330 hasConcept C2908647359 @default.
• W3006638330 hasConcept C526805850 @default.
• W3006638330 hasConcept C71924100 @default.
• W3006638330 hasConcept C72563966 @default.
• W3006638330 hasConcept C99454951 @default.
• W3006638330 hasConceptScore W3006638330C121608353 @default.
• W3006638330 hasConceptScore W3006638330C126322002 @default.
• W3006638330 hasConceptScore W3006638330C143998085 @default.
• W3006638330 hasConceptScore W3006638330C197934379 @default.
• W3006638330 hasConceptScore W3006638330C2776694085 @default.
• W3006638330 hasConceptScore W3006638330C2777063308 @default.
• W3006638330 hasConceptScore W3006638330C2777148230 @default.
• W3006638330 hasConceptScore W3006638330C2780210213 @default.
• W3006638330 hasConceptScore W3006638330C2780258809 @default.

• next